BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 27256431)

  • 1. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.
    Qiu W; Christakis I; Silva A; Bassett RL; Cao L; Meng QH; Gardner Grubbs E; Zhao H; Yao JC; Lee JE; Perrier ND
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):400-7. PubMed ID: 27256431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients.
    de Laat JM; Pieterman CR; Weijmans M; Hermus AR; Dekkers OM; de Herder WW; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4143-51. PubMed ID: 23956349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?
    Qiu W; Christakis I; Stewart AA; Vodopivec DM; Silva-Figueroa A; Chen H; Woodard TL; Halperin DM; Lee JE; Yao JC; Perrier ND
    Clin Endocrinol (Oxf); 2017 Jun; 86(6):791-797. PubMed ID: 28273369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
    Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
    Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group.
    Klein Haneveld MJ; van Treijen MJC; Pieterman CRC; Dekkers OM; van de Ven A; de Herder WW; Zandee WT; Drent ML; Bisschop PH; Havekes B; Vriens MR; Verrijn Stuart AA; Valk GD; van Leeuwaarde RS
    J Clin Endocrinol Metab; 2021 Nov; 106(12):3515-3525. PubMed ID: 34333645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
    Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
    BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors.
    Kfir SK; Halperin R; Percik R; Uri I; Halpern N; Shlomai G; Laish I; Tirosh A; Tirosh A
    Horm Metab Res; 2021 May; 53(5):319-325. PubMed ID: 33878789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
    Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
    Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?
    Challis BG; Casey RT; Grossman A; Newell-Price J; Newey P; Thakker RV
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):708-715. PubMed ID: 31505044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
    Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
    Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.
    Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.
    Nikou GC; Marinou K; Thomakos P; Papageorgiou D; Sanzanidis V; Nikolaou P; Kosmidis C; Moulakakis A; Mallas E
    Pancreatology; 2008; 8(4-5):510-9. PubMed ID: 18765956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.
    Panzuto F; Severi C; Cannizzaro R; Falconi M; Angeletti S; Pasquali A; Corleto VD; Annibale B; Buonadonna A; Pederzoli P; Delle Fave G
    J Endocrinol Invest; 2004 Jan; 27(1):6-11. PubMed ID: 15053236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
    Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
    J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.
    Chiloiro S; Lanza F; Bianchi A; Schinzari G; Brizi MG; Giampietro A; Rufini V; Inzani F; Giordano A; Rindi G; Pontecorvi A; De Marinis L
    Endocrine; 2018 May; 60(2):362-367. PubMed ID: 28567607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AACE/ACE disease state clinical review: pancreatic neuroendocrine incidentalomas.
    Herrera MF; Åkerström G; Angelos P; Grant CS; Hoff AO; Pantoja JP; Pérez-Johnston R; Sahani DV; Wong RJ; Randolph G
    Endocr Pract; 2015 May; 21(5):546-53. PubMed ID: 25962093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
    Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR
    J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1.
    Oberg K; Skogseid B
    J Intern Med; 1998 Jun; 243(6):471-6. PubMed ID: 9681845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.